Globus Medical (NYSE:GMED) said the FDA issued a warning letter last month over its MicroFuse bone-growth putty, sending share prices down today on Wall Street.
Globus Medical
DePuy Synthes pursues more ex-sales reps, Globus
Legal loss pushes Globus Medical’s Q2 earnings down
Globus Medical (NYSE:GMED) shares rose more than 2% last week despite a 61% 2nd-quarter profit slide after the medical device company reported earnings above Wall Street’s forecast and confirmed its outlook for the rest of the year.
DePuy goes after ex-sales reps now working for Globus distributor Sky Surgical
Can 2nd-tier spinal companies grow in a challenging sector?
Stephen Simpson
J&J’s Synthes unit wins $16M ruling in patent fight with Globus Medical
MassDevice.com +7 | The top 7 med-tech stories for the week of May 13, 2013
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Globus Medical sues J&J’s DePuy Synthes unit over spine implant patent
NuVasive takes on another former sales rep
Spine: Globus Medical’s sales up, profits down in Q3
Globus Medical (NYSE:GMED) said profits dropped slightly during the 3rd quarter, despite a 12.5% increase in sales for the Audubon, Pa.-based orthopedic medical device company.
Spine: Globus Medical lands FDA approval for implant
Globus Medical (NYSE:GMED) won pre-market approval from the FDA for its Secure-C artificial cervical disc, based on a study showing that the spinal implant performed